## **Pharmacy and Therapeutics Committee Meeting Record**

**Date:** 11/21/03 **Time:** 9:00 a.m. – 5:00 p.m. **Location:** 700 West State Street, East Conference Room **Moderator:** Thomas R. Young, M.D.

Committee Members Present: Thomas R. Young, M.D.; Richard Pines, D.O.; George Pfoertner, M.D.; Catherine Gundlach, PharmD; Jeffery Edwards, M.D.; Rick Sutton, RPh; Richard Markuson, RPh; Bob Comstock, RPh; Thomas Rau, M.D.; Shawna Kittridge, MHS, RPh; Steve Montamat, M.D.

Committee Members Absent: James Schroeder, P.A.

Agenda Item	Presenter	Outcome/Action	Assigned	Due
CALL TO ORDER	Thomas R. Young, M.D.			
Roll Call		Dr. Young called the roll.		
Reading of Confidentiality Statement		The confidentiality statement was read by Dr. Young.		
• Approval of Minutes from October 17, 2003, Meeting		The minutes from the October 17, 2003, committee meeting were approved with no changes.		
<ul> <li>Review of 2004 Committee Meeting Dates</li> <li>Discussion of Clinical Questions for ARBS and SSRI</li> </ul>		The future proposed meeting dates were included in committee member packets. The meetings dates were agreed to and will be posted on the website. Those dates are:  • January 16, 2004 • March 19, 2004 • May 21, 2004 • July 16, 2004  A draft of key questions and inclusion criteria for angiotensin receptor blockers (ARBs) and SSRIs/2 <sup>nd</sup> generation antidepressants were distributed to committee members in their packets. Dr. Montamat went through both documents with the committee.		
		<ol> <li>ACTION:</li> <li>Dr. Montamat will revise Question 5 under inclusion criteria for ARBs.</li> <li>Any questions or comments that committee members have regarding the draft questions and inclusion criteria will be sent to Dr. Montamat and Tami Eide via email prior to December 4.</li> </ol>	Dr. Montamat  Committee  Members	12/5/03 12/4/03

Agenda Item	Presenter	Outcome/Action	Assigned	Due
DRUG CLASS REVIEW	Tami Eide, Pharm.D., BCPS, FASHP			
• Statins	TASH	Tami Eide presented slides explaining the review of statins, including indications, how the drugs work, the drug-drug interactions, availability and dosing, and the proposed Medicaid prior authorization guidelines. This review included the following drugs:		
		<ul> <li>Atorvastatin</li> <li>Fluvastatin</li> <li>Lovastatin</li> <li>Pravastatin</li> <li>Simvastatin</li> </ul>		
REVIEW OF CLINICAL DATA	Mark Helfand, M.D.			
• Statins		Dr. Helfand presented information explaining the clinical data for statins, including the study's conclusion. A copy of the information discussed was included in committee member packets. This report is scheduled to expire on December 31, 2003. An updated report should be completed by that expiration date and it is anticipated that this updated report will include information regarding the newer medication.		
DRUG CLASS REVIEW	Tami Eide, Pharm.D., BCPS, FASHP			
• Triptans		Tami Eide presented slides explaining the review of triptans, including indications, how the drugs work, the drug-drug interactions, availability and dosing, and the proposed Medicaid prior authorization guidelines. This review included the following drugs:  - Almotriptan - Electriptan - Frovatriptan - Naratriptan - Rizatriptan - Sumatriptan		
DEVIEW OF CLINICAL DATA	Mork Holford M.D.	Zomitriptan		
REVIEW OF CLINICAL DATA	Mark Helfand, M.D.			
• Triptans		Dr. Helfand presented information explaining the clinical data for triptans, including the study's conclusion. A copy of		

Agenda Item	Presenter	Outcome/Action	Assigned	Due
		the information discussed was included in committee member packets. The report presented expired on October 31, 2003; however, the preliminary update report was also included in committee member packets.		
PUBLIC COMMENT PERIOD	Thomas R. Young, M.D.	Nine people were listed to speak during the public comment period. Public comment was received from the following:		
		<ul> <li>Dave Beaman, PharmD, Astra Zeneca – Triptans and Statins</li> <li>Marilyn Semechuck, PharmD, Glaxo-Smith-Kline - Triptans</li> <li>Linda Vorick, M.D., Merck – Triptans and Statins</li> <li>Ome Oebru, PharmD, Bristol-Myers-Squibb – Statins</li> <li>Roy Palmer, Ph.D., Pfizer – Statins</li> <li>Mark Duerre, Andrx Labs – Statins</li> <li>Dr. Robert Popoula, Pfizer – Triptans</li> </ul>		
		Norm Brown, Glaxo-Smith-Kline – Triptans		
COMMITTEE RECOMMENDATION FOR SELECTED THERAPEUTIC CLASSES	Thomas R. Young, M.D.	Statins The committee determined that fundamentally any one of the statins was a drug they would give a patient and that there are several factors to think about when looking at statins. These factors include lipid lowering, cardiac endpoint, drug interaction, and cost effectiveness. The committee was asked if there are one or more drugs that are clinically better and that Medicaid should look at. The committee determined that each drug has similar efficacy; however, it is noted that Pravastatin is safer in drug interactions.  Triptans The committee determined that all drugs in this class are efficacious; however, it appears that Rizatriptan has more clinically significant advantages than the other drugs in this group.		
SUPPLEMENTAL REBATE INFORMATION (CLOSED TO PUBLIC)	Shawna Kittridge, MHS, RPh	Shawna Kittridge presented supplemental rebate information to the committee members for their review and discussion. This review and discussion was closed to the public.		
COMMITTEE FINAL RECOMMENDATION FOR THERAPEUTIC CLASSES	Thomas R. Young, M.D.	Committee final recommendation for statins is Scenario L: Lescol/XL, Lovastatin, Pravachol, Advicor, and Altocor. If there is no improvement with one preferred agent within six months, another agent can be used.  Committee final recommendation for triptans is Scenario C:		

Agenda Item	Presenter	Outcome/Action	Assigned	Due
		Imitrex, Maxalt/MLT, and Zomig/ZMT. If there is failure of		
		all three preferred agents, another agent can be used.		
ADJOURN COMMITTEE MEETING	Thomas R. Young, M.D.	The committee meeting was adjourned. The next committee		
	_	meeting is scheduled for January 16, 2004.		